Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05617859

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure

Sponsor: Henan Cancer Hospital

Conditions Effectiveness Sexuality

Interventions Lenvatinib mesylate capsule

Updated 7 times since 2022 Last updated: Aug 17, 2023 Started: Apr 30, 2023 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05617859, this PHASE2 trial focuses on Effectiveness and Sexuality and remains actively recruiting participants. Sponsored by Henan Cancer Hospital, it has been updated 7 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Not Yet Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2023 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2
Dec 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Cancer Hospital

Data source: Henan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China